Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine is a synthetic small molecule peptide composed of L-threonine and L-isoleucine residues linked to an epoxide-containing ethoxycarbonyl group. It belongs to the class of organic compounds known as peptides and has a molecular formula of C16H26N2O8 with a monoisotopic mass of approximately 374.17 Da[2][6][10]. There is no evidence that this compound has been approved for clinical use or entered advanced stages of drug development; it appears in chemical databases as an experimental or research compound with no reported pharmacological mechanism, clinical indication, or developer[9]. Its structure suggests potential utility in biochemical research or as a tool compound but not as an established pharmaceutical agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine.